Physician

Tudor Ocneanu, MD

According to 2025 Medicare claims, Tudor Ocneanu, MD (NPI: 1073573507) practices internal medicine in the Santa Fe, NM market, with the plurality of this provider's patient population coming from Santa Fe, NM. This provider's primary affiliated billing organization is NEPHROPHILES LLC (NPI: 1124133129; TIN: 85-0303623) and primary practice location at 87505-6309.

Ocneanu's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 691 traditional Medicare patients, billed 3,314 HCPCS/CPT codes, and received $238,310 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 4,168 prescription claims across 674 beneficiaries totaling $539,894 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 36 claims. Open Payments data shows 52 records totaling $1,540. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $176,879 to $539,894. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $3,293 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	520	2,691	$291,268
2016	578	2,888	$313,948
2017	595	2,811	$297,658
2018	619	2,614	$274,338
2019	687	2,499	$264,983
2020	725	2,839	$282,075
2021	875	2,793	$288,927
2022	931	3,364	$307,711
2023	536	2,103	$196,122
2024	691	3,314	$238,310

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	316	1,558	$176,879
2016	374	2,093	$230,787
2017	427	2,558	$298,488
2018	505	2,947	$281,675
2019	566	3,432	$286,538
2020	616	3,582	$308,124
2021	637	3,696	$275,110
2022	575	2,955	$242,912
2023	551	3,035	$349,037
2024	674	4,168	$539,894

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	182	$16,369
2016	N/R	149	$6,706
2017	N/R	91	$4,164
2018	N/R	43	$2,092
2019	N/R	66	$2,506
2020	N/R	56	$1,832
2021	N/R	48	$1,365
2022	N/R	N/R	N/R
2023	N/R	15	$111
2024	N/R	36	$430

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	85	164	$126
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	108	371	$96
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	399	747	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	118	130	$62
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	337	498	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	115	5,530	$102,497
Jardiance	Empagliflozin	100	5,113	$101,421
Velphoro	Sucroferric Oxyhydroxide	16	960	$74,144
Veltassa	Patiromer Calcium Sorbitex	36	1,633	$44,228
Kerendia	Finerenone	46	1,890	$40,005

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$209
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$150
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	12	$71

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	52	$1,540	Bayer Healthcare Pharmaceuticals Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Tudor Ocneanu, MD?

Tedicare shows public-source Medicare data for Tudor Ocneanu, MD (NPI 1073573507), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Tudor Ocneanu, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Tudor Ocneanu, MD?

Tudor Ocneanu, MD is linked to NEPHROPHILES LLC (billing NPI 1124133129) in the available physician profile data.

Does Tudor Ocneanu, MD have Open Payments data?

Tudor Ocneanu, MD has 52 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.